Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
140

Summary

Conditions
  • Cutaneous Squamous Cell Carcinoma
  • Advanced Solid Tumors
  • Anal Carcinoma
  • Nasopharyngeal Carcinoma
  • Basal Cell Carcinoma (Unresectable or Metastatic)
  • Urothelial Carcinoma, HCC
  • Sarcomatoid Renal Cell Carcinoma
  • Cervical Cancer
  • Clear Cell Ovarian or Endometrial Carcinoma
  • Cyclin-dependent Kinase 12 Mutated Tumors
  • DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)
  • MSI-H/dMMR Tumors
  • Esophageal Squamous Cell Carcinoma
  • Merkel Cell Carcinoma
  • PD-L1 Amplified Tumor (9p24.1)
  • Squamous Cell Penile Carcinoma
  • Mesothelioma
  • Small Cell Lung Cancer
Type
Interventional
Phase
Phase 1
Design
Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: The study consists of 2 parts. Part 1 is a dose-escalation design to identify the maximum tolerated dose and/or pharmacologically active dose for INCB099318. Part 2 is an expansion at 1 or more dose levels to further explore safety, preliminary efficacy, pharmacoketics, and pharmacodynamic effects.Masking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

Not Provided

Not Provided

Tracking Information

NCT #
NCT04272034
Collaborators
Not Provided
Investigators
Study Director: Louis Viviers, MD Incyte Corporation